Biochemistry & Molecular Biology Journal Open Access

  • ISSN: 2471-8084
  • Journal h-index: 12
  • Journal CiteScore: 2.55
  • Journal Impact Factor: 1.74
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Cancer and tumor immunology

International Conference on Biotechnology, Biomarkers & Systems Biology
March 04-05, 2019 | Amsterdam, Netherlands

Sudha Bansode

Shankarrao Mohite College, India

Posters & Accepted Abstracts: Biochem Mol biol J

Abstract:

Substantiation of the potential relevance to cancer of the list of 115 proteins identified as being targeted solely by tumor selective compounds was performed by two independent perspectives. On the one hand, all 115 proteins were scored on the basis of recently derived oncogene probabilities (Oncoscores) and checked for currently available experimental data on the upand down-regulation in colon cancer samples. On the other hand, we used all drug target interaction data available from public resources to rank order all drugs based on the number of known targets within the list of 115 proteins and check for whether cancer was the primary indication among the top ranked. The results provide ample support for the use of the DIVISS approach to identifying cancer-relevant targets. A cancer marker or tumor marker is a biomarker found in blood, pee, or body tissues that can be raised by the proximity of at least one sorts of development. There are different tumor markers, each illustrative of a particular alignment. In addition to their use in cancer medicine, biomarkers are often used throughout the cancer drug discovery process. For instance, in the 1960s, researchers discovered the majority of patients with chronic myelogenous leukemia possessed a particular genetic abnormality.

Biography :

E-mail:

drsudhabanasode@yahoo.com